Inogen Inc. (NASDAQ:INGN) VP Byron Myers sold 6,200 shares of Inogen stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $60.04, for a total transaction of $372,248.00. Following the completion of the transaction, the vice president now directly owns 41,385 shares in the company, valued at $2,484,755.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Byron Myers also recently made the following trade(s):
- On Friday, September 9th, Byron Myers sold 3,800 shares of Inogen stock. The stock was sold at an average price of $60.07, for a total transaction of $228,266.00.
- On Tuesday, August 9th, Byron Myers sold 13,000 shares of Inogen stock. The stock was sold at an average price of $55.00, for a total transaction of $715,000.00.
Inogen Inc. (NASDAQ:INGN) opened at 60.20 on Thursday. The company’s 50-day moving average is $57.61 and its 200-day moving average is $49.64. Inogen Inc. has a 12 month low of $28.81 and a 12 month high of $60.95. The stock has a market capitalization of $1.21 billion, a P/E ratio of 88.53 and a beta of 0.88.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The company had revenue of $54.57 million for the quarter, compared to the consensus estimate of $52.44 million. During the same period in the prior year, the company posted $0.17 EPS. The company’s revenue was up 23.9% compared to the same quarter last year. Equities analysts anticipate that Inogen Inc. will post $0.63 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC increased its position in Inogen by 0.9% in the first quarter. TIAA CREF Investment Management LLC now owns 100,661 shares of the medical technology company’s stock worth $4,528,000 after buying an additional 940 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Inogen by 66.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 6,000 shares of the medical technology company’s stock worth $301,000 after buying an additional 2,400 shares during the last quarter. Bayesian Capital Management LP acquired a new position in Inogen during the first quarter worth about $238,000. Bogle Investment Management L P DE acquired a new position in Inogen during the first quarter worth about $861,000. Finally, Geode Capital Management LLC increased its position in Inogen by 8.1% in the first quarter. Geode Capital Management LLC now owns 149,106 shares of the medical technology company’s stock worth $6,706,000 after buying an additional 11,169 shares during the last quarter.
Several research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. Needham & Company LLC reissued a “strong-buy” rating and issued a $64.00 target price (up from $58.00) on shares of Inogen in a research report on Sunday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of Inogen from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Stifel Nicolaus downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. They noted that the move was a valuation call. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Inogen in a research report on Wednesday, June 8th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $55.00.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.